These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 32454224)

  • 1. Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation.
    Chen D; Ye Z; Wang C; Wang Q; Wang H; Kuek V; Wang Z; Qiu H; Yuan J; Kenny J; Yang F; He J; Liu Y; Wang G; Zhang M; Zhang G; Wang J; Chen P; Xu J
    Pharmacol Res; 2020 Sep; 159():104944. PubMed ID: 32454224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways.
    Chen G; Xu Q; Dai M; Liu X
    Biochem Biophys Res Commun; 2019 Feb; 509(2):329-334. PubMed ID: 30579598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GSH attenuates RANKL-induced osteoclast formation in vitro and LPS-induced bone loss in vivo.
    Han B; Geng H; Liu L; Wu Z; Wang Y
    Biomed Pharmacother; 2020 Aug; 128():110305. PubMed ID: 32485573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel RANKL-targeted flavonoid glycoside prevents osteoporosis through inhibiting NFATc1 and reactive oxygen species.
    Hong G; Chen Z; Han X; Zhou L; Pang F; Wu R; Shen Y; He X; Hong Z; Li Z; He W; Wei Q
    Clin Transl Med; 2021 May; 11(5):e392. PubMed ID: 34047464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyanidin Chloride inhibits ovariectomy-induced osteoporosis by suppressing RANKL-mediated osteoclastogenesis and associated signaling pathways.
    Cheng J; Zhou L; Liu Q; Tickner J; Tan Z; Li X; Liu M; Lin X; Wang T; Pavlos NJ; Zhao J; Xu J
    J Cell Physiol; 2018 Mar; 233(3):2502-2512. PubMed ID: 28771720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities.
    Liu Y; Wang C; Wang G; Sun Y; Deng Z; Chen L; Chen K; Tickner J; Kenny J; Song D; Zhang Q; Wang H; Chen Z; Zhou C; He W; Xu J
    Theranostics; 2019; 9(16):4648-4662. PubMed ID: 31367247
    [No Abstract]   [Full Text] [Related]  

  • 8. Dauricine attenuates ovariectomized-induced bone loss and RANKL-induced osteoclastogenesis via inhibiting ROS-mediated NF-κB and NFATc1 activity.
    Lin X; Yuan G; Yang B; Xie C; Zhou Z; Liu Y; Liu Z; Wu Z; Akimoto Y; Li N; Xu R; Song F
    Phytomedicine; 2024 Jul; 129():155559. PubMed ID: 38579642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KMUP-1 suppresses RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss: roles of MAPKs, Akt, NF-κB and calcium/calcineurin/NFATc1 pathways.
    Liou SF; Hsu JH; Lin IL; Ho ML; Hsu PC; Chen LW; Chen IJ; Yeh JL
    PLoS One; 2013; 8(7):e69468. PubMed ID: 23936022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
    Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
    J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production.
    Lee SY; Lee KS; Yi SH; Kook SH; Lee JC
    PLoS One; 2013; 8(12):e80873. PubMed ID: 24324641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kirenol inhibits RANKL-induced osteoclastogenesis and prevents ovariectomized-induced osteoporosis via suppressing the Ca
    Zou B; Zheng J; Deng W; Tan Y; Jie L; Qu Y; Yang Q; Ke M; Ding Z; Chen Y; Yu Q; Li X
    Phytomedicine; 2021 Jan; 80():153377. PubMed ID: 33126167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (-)-Epigallocatechin-3-gallate inhibits RANKL-induced osteoclastogenesis via downregulation of NFATc1 and suppression of HO-1-HMGB1-RAGE pathway.
    Nishioku T; Kubo T; Kamada T; Okamoto K; Tsukuba T; Uto T; Shoyama Y
    Biomed Res; 2020; 41(6):269-277. PubMed ID: 33268671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hinokitiol inhibits RANKL-induced osteoclastogenesis in vitro and prevents ovariectomy-induced bone loss in vivo.
    Wang Y; Yang Q; Fu Z; Sun P; Zhang T; Wang K; Li X; Qian Y
    Int Immunopharmacol; 2021 Jul; 96():107619. PubMed ID: 33831806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseurotin A Inhibits Osteoclastogenesis and Prevents Ovariectomized-Induced Bone Loss by Suppressing Reactive Oxygen Species.
    Chen K; Qiu P; Yuan Y; Zheng L; He J; Wang C; Guo Q; Kenny J; Liu Q; Zhao J; Chen J; Tickner J; Fan S; Lin X; Xu J
    Theranostics; 2019; 9(6):1634-1650. PubMed ID: 31037128
    [No Abstract]   [Full Text] [Related]  

  • 18. Vinpocetine inhibits RANKL-induced osteoclastogenesis and attenuates ovariectomy-induced bone loss.
    Zhu M; Liu H; Sun K; Liu J; Mou Y; Qi D; Zhou C; Abudunaibi M; Tasiken B; Li J; Cheng H; Huang H
    Biomed Pharmacother; 2020 Mar; 123():109769. PubMed ID: 31846839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agrimophol suppresses RANKL-mediated osteoclastogenesis through Blimp1-Bcl6 axis and prevents inflammatory bone loss in mice.
    Cao J; Wang S; Wei C; Lin H; Zhang C; Gao Y; Xu Z; Cheng Z; Sun WC; Wang HB
    Int Immunopharmacol; 2021 Jan; 90():107137. PubMed ID: 33199235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cajaninstilbene acid inhibits osteoporosis through suppressing osteoclast formation and RANKL-induced signaling pathways.
    Sun Y; Liu Y; He W; Wang C; Tickner J; Kuek V; Zhou C; Wang H; Zou X; Hong Z; Yang F; Shao M; Chen L; Xu J
    J Cell Physiol; 2019 Jul; 234(7):11792-11804. PubMed ID: 30515822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.